Penumbra Stock (NYSE:PEN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$319.83

52W Range

$221.26 - $362.41

50D Avg

$319.10

200D Avg

$315.63

Market Cap

$12.63B

Avg Vol (3M)

$413.46K

Beta

0.70

Div Yield

-

PEN Company Profile


Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

4,700

IPO Date

Sep 18, 2015

Website

PEN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Dec 20
Neuro$347.74M$338.71M$292.63M
Peripheral Vascular$499.39M$408.88M$267.78M

Fiscal year ends in Dec 25 | Currency in USD

PEN Financial Summary


Dec 25Dec 24Dec 23
Revenue$1.40B$1.19B$1.06B
Operating Income$189.25M$9.28M$73.55M
Net Income$177.69M$14.01M$90.95M
EBITDA$189.25M$45.99M$108.65M
Basic EPS$4.57$0.36$2.37
Diluted EPS$4.52$0.36$2.32

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q3 25Nov 05, 25 | 4:30 PM
Q2 25Jul 29, 25 | 4:30 PM
Q1 25Apr 23, 25 | 4:30 PM

Peer Comparison


TickerCompany
HIMSHims & Hers Health, Inc.
BIOBio-Rad Laboratories, Inc.
BAXBaxter International Inc.
DVADaVita Inc.
GMEDGlobus Medical, Inc.
HQYHealthEquity, Inc.
CRLCharles River Laboratories International, Inc.
ALGNAlign Technology, Inc.
HSICHenry Schein, Inc.